# INTerpath-014: what one clinician is saying

> 79 statements from 18 sources (2 videos, 16 posts), 1 of them from 1 confirmed clinician, each linked to its source. Commentary checked Nov 22, 2026.

## Report

- Trial: A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)
- NCT ID: NCT07513376
- Registry: https://clinicaltrials.gov/study/NCT07513376
- Sponsor: Merck Sharp & Dohme LLC
- Phase: Phase 3
- Status: Recruiting
- Drugs tested: intismeran autogene plus MK-3475A; intismeran autogene
- Indication: resected high-risk stage I non-small cell lung cancer
- Version: v1.0.0, edition 1
- Accepted: 2026-11-22 UTC
- Last checked: 2026-11-22 UTC
- Release hash: 9bd4cd18fd851b00956dcad585ec8613464af354451493d2a76c50bee115fa79

## Counts

- Commentary sources screened: 22
- Sources cited by verified statements: 18
- Verified statements: 79
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 1
- Findings: 10
- Named people in screened sources (unnamed speakers and accounts not counted): 3
- Speakers cited: 3
- Cited speakers with a verified identity: 2
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 1
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 1
- By role and specialty (the abstract's specialty counts):
  - 1 physician, specialty not confirmed
- Organisational or shared accounts (not counted as people): 3

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

For INTerpath-014, a speaker regards benefit without pembrolizumab as unresolved because earlier melanoma signals arose with combination treatment, while another asserts intismeran requires pembrolizumab. Their clinical roles are not established, and the commentary offers no assessment of the trial’s benefit or tolerability.

## Findings (titles)

- F1. Vaccine monotherapy: what speakers say
  - 7 statements from 1 speaker in 5 sources.
  - No named clinician · accounts and unnamed speakers.
- F2. INTerpath-014: some speakers see design information, not a lung efficacy readout
  - 8 statements in 7 sources.
  - No named speaker is counted in this finding: its title's view comes from speakers the source does not name.
  - No named clinician · accounts and unnamed speakers.
- F3. High-risk stage I NSCLC: why speakers welcome testing treatment earlier
  - 4 statements from 2 speakers in 2 sources.
  - 2 of the 2 named speakers in this finding hold this view.
  - 1 of the report's 1 cited clinicians.
- F4. Intismeran supply: speakers see limits, but one accepts the launch case
  - 9 statements in 4 sources, 1 of them a podcast or video.
  - No named speaker is counted in this finding: its title's view comes from speakers the source does not name.
  - No named clinician · accounts and unnamed speakers.
- F5. SC use: a speaker cites IV time, and one sees franchise value if it works
  - 4 statements in 3 sources.
  - No named speaker is counted in this finding: its title's view comes from speakers the source does not name.
  - No named clinician · accounts and unnamed speakers.
- F6. Trial access: what speakers say
  - 15 statements in 2 sources, all podcasts or videos.
  - No named clinician · accounts and unnamed speakers.
- F9. Colorectal vaccine data: speakers limit extrapolation, but stress PD-1 context
  - 8 statements in 2 sources.
  - No named speaker is counted in this finding: its title's view comes from speakers the source does not name.
  - No named clinician · accounts and unnamed speakers.
- F10. Commercial expectations: what speakers say
  - 10 statements from 1 speaker in 6 sources.
  - No named clinician · accounts and unnamed speakers.

### Beyond the trial population

- F7. Lung vaccines: why a speaker expects no edge over neoadjuvant checkpoint inhibition
  - 2 statements in 2 sources.
  - No named speaker is counted in this finding: its title's view comes from speakers the source does not name.
  - No named clinician · accounts and unnamed speakers.
- F8. Melanoma: most speakers need lung data; most see conditional trial support
  - 20 statements in 5 sources, 1 of them a podcast or video.
  - No named speaker is counted in this finding: its title's view comes from speakers the source does not name.
  - No named clinician · accounts and unnamed speakers.

2 of the 10 findings and 20 of the 79 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 7 | 6 | 5 | 1 | 2 |
| F2 | 8 | 7 | 7 | 0 | 3 |
| F3 | 4 | 2 | 2 | 2 | 3 |
| F4 | 9 | 4 | 4 | 0 | 5 |
| F5 | 4 | 3 | 3 | 0 | 3 |
| F6 | 15 | 4 | 2 | 0 | 4 |
| F9 | 8 | 3 | 2 | 0 | 3 |
| F10 | 10 | 6 | 6 | 1 | 3 |
| F7 | 2 | 2 | 2 | 0 | 2 |
| F8 | 20 | 7 | 5 | 0 | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 3 | 0 | 0 | 2 | 2 | 8 | 0 | 5 posts and articles |
| F2 | 2 | 2 | 0 | 0 | 4 | 10 | 0 | 7 posts and articles |
| F3 | 2 | 0 | 2 | 0 | 0 | 4 | 0 | 2 posts and articles |
| F4 | 3 | 0 | 0 | 0 | 6 | 13 | 0 | 3 posts and articles, 1 podcast or video |
| F5 | 2 | 0 | 0 | 1 | 1 | 6 | 0 | 3 posts and articles |
| F6 | 7 | 0 | 0 | 0 | 8 | 15 | 1 | 2 podcasts and video |
| F9 | 2 | 1 | 0 | 3 | 2 | 8 | 0 | 2 posts and articles |
| F10 | 6 | 1 | 0 | 0 | 3 | 15 | 0 | 6 posts and articles |
| F7 | 0 | 1 | 0 | 1 | 0 | 2 | 1 | 2 posts and articles |
| F8 | 10 | 4 | 0 | 0 | 6 | 20 | 1 | 4 posts and articles, 1 podcast or video |

### Trial dimensions

- Primary endpoint: Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review (BICR) in Participants With Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Arm A and Arm C: F1 (2 shared claims), F2 (1 shared claims), F9 (2 shared claims)
- Secondary endpoints: no finding draws on it directly
- Population and setting: F1 (1 shared claims), F2 (1 shared claims), F3 (3 shared claims), F4 (1 shared claims), F6 (5 shared claims), F9 (1 shared claims)
- The comparison: F1 (7 shared claims), F5 (1 shared claims), F9 (2 shared claims), F10 (1 shared claims)
- Safety and tolerability: no finding draws on it directly
- Design and conduct: F2 (8 shared claims), F3 (2 shared claims), F10 (2 shared claims)

## Abbreviations

- BICR: blinded independent central review
- DFS: disease-free survival
- HCP: healthcare professional
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- NSCLC: non-small cell lung cancer

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 10 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 79 | Paid |
| Who said each statement: the cited speakers | 3 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 1 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 2 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 12 | Free |
| Sources with links | 18 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 1 of the 3 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

10 discussed · 2 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review (BICR) in Participants With Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Arm A and Arm C | discussed | 4 | 4 |
| Secondary endpoints | no commentary found | 0 | 0 |
| Population and setting | discussed | 12 | 9 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 9 | 6 |
| Safety and tolerability | no commentary found | 0 | 0 |
| Design and conduct | discussed | 10 | 8 |
| Postoperative manufacturing, tissue and timing | discussed | 10 | 4 |
| Administration route and workflow | discussed | 4 | 3 |
| Research access, eligibility review and patient support | discussed | 15 | 3 |
| Cross-cancer expectations, mutation burden and vaccine-only uncertainty | discussed | 28 | 6 |
| Commercial expectations and economic uncertainty | discussed | 8 | 6 |
| Comparison with neoadjuvant checkpoint blockade | discussed | 2 | 2 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 20 statements · 25%** | | | |
| YouTube | 20 | 2 | 2 |
| **Posts · 59 statements · 75%** | | | |
| X threads | 56 | 15 | 19 |
| LinkedIn posts | 3 | 1 | 1 |

- Screened window: 2026-04-27 to 2026-10-26
- Cited window: 2026-04-27 to 2026-10-26
- Retrieved: 2026-11-22

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)
- Registry: NCT07513376 (https://clinicaltrials.gov/study/NCT07513376)
- Study IDs: V940-014 · U1111-1323-9950 (UTN) · 2025-522643-18-00 (EU CT) · jRCT2021260028 (Japan Registry of Clinical Trials (jRCT))
- Sponsor: Merck Sharp & Dohme LLC
- Collaborators: ModernaTX, Inc.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 876 (estimated)
- Start: 2026-05-04 (actual)
- Primary completion: 2034-08-22 (estimated)
- Primary endpoint: Disease-Free Survival (DFS) as Assessed by Blinded Independent Central Review (BICR) in Participants With Nonsquamous Non-Small Cell Lung Cancer (NSCLC) in Arm A and Arm C (Up to approximately 98 months)
- Intervention: Intismeran (biological)
- Intervention: Pembrolizumab coformulated with berahyaluronidase alfa (biological)
- Intervention: Placebo (other)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a view on perioperative immunotherapy evidence and testing, capacity and access barriers in resectable lung cancer; a view on actual vaccine receipt and time to dosing when evaluating adjuvant vaccination.
- 17 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 43 sources about other trials or topics are not included.
- The sources reviewed for this edition are selected public discussions, not a representative sample of HCP views. Repeated posts by one account do not establish independent agreement.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The exact trial protocol and a results publication for NCT07513376 were not found in the reviewed materials. The cited congress statements describe trial design rather than efficacy results and do not provide an INTerpath-014 safety assessment.
- Exact product labels were not available for independent assessment of approval-scope statements. Access, pricing and regulatory expectations remain attributed, time-specific accounts.
- Melanoma subgroup findings and comparisons with another vaccine in colorectal cancer are exploratory or cross-trial context, not evidence of benefit or harm in INTerpath-014.
- Source accounts differ on study-start timing. The August 2034 primary-completion date is an estimate, and an account's eight-year readout interpretation is not a guaranteed timetable.
- The neoadjuvant comparison does not include a full account of the connected perioperative-immunotherapy evidence or concerns about testing, capacity and access; it should not be read as a comprehensive comparison.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-22 UTC: current edition
  - Routine maintenance: 2 fixes (names, counts, tags, text):
    - 2026-11-22 UTC: The trial's name is spelled as its investigators write it, “INTerpath-014” (NCT07513376), outside quotations (was “INTERpath”, “INTERpath-014”).
    - 2026-11-22 UTC: taxonomy mapping corrected

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-22 UTC. No changes.

## Offer

- Size: Focused · 79 verified statements · 1 from 1 confirmed clinician
- Not for sale: This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it, by any route; a later edition that reaches the minimum is for sale at its normal price. Follow the change feed: https://www.erudio.com/reports/interpath-014-nct07513376/feed.json
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=interpath-014-nct07513376

## Cite

Erudio Health. INTerpath-014 (NCT07513376): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 22, 2026. https://www.erudio.com/reports/interpath-014-nct07513376

## Questions

### How much does the INTerpath-014 report cost?

This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.

### What does the INTerpath-014 report cover?

79 statements from 18 sources (2 videos, 16 posts), 1 of them from 1 confirmed clinician, each linked to its source. Commentary checked Nov 22, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the INTerpath-014 report?

Its preview, yes: get_report_card({ "slug": "interpath-014-nct07513376" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the INTerpath-014 report?

Edition 1 (version 1.0.0), accepted Nov 22, 2026 UTC; last checked for new commentary Nov 22, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/interpath-014-nct07513376.json
- Markdown: https://www.erudio.com/reports/interpath-014-nct07513376.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/interpath-014-nct07513376/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "interpath-014-nct07513376"}`
